What is it about?
Serum periostin was comparable between asthma and ACO, while YKL-40 was comparable between ACO and COPD. The proportion of patients with high levels of both biomarkers was greater in ACO than in asthma or COPD.
Featured Image
Why is it important?
Asthma-COPD overlap (ACO) has been proposed as a different diagnosis from asthma and COPD. However, little is known about the role of serum biomarkers in ACO.
Read the Original
This page is a summary of: Combined assessment of serum periostin and YKL-40 may identify asthma-COPD overlap, The Journal of Allergy and Clinical Immunology In Practice, July 2018, Elsevier,
DOI: 10.1016/j.jaip.2018.06.015.
You can read the full text:
Resources
Related article
A clustering approach to identify and characterize the asthma and chronic obstructive pulmonary disease overlap phenotype
Related article
Association between (CCTTT)n repeat polymorphism in NOS2 promoter and asthma exacerbations
Share Link
a personalized URL providing 50 days' free access to the article
Contributors
The following have contributed to this page
